KRAS MUTATION-RELATED TUMORS
Clinical trials for KRAS MUTATION-RELATED TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS MUTATION-RELATED TUMORS trials appear
Sign up with your email to follow new studies for KRAS MUTATION-RELATED TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Scientists test novel combo against Tough-to-Treat tumors
Disease control Recruiting nowThis early-stage trial is testing the safety and initial effectiveness of a new two-drug combination (NEROFE plus doxorubicin) for patients with advanced solid tumors that have specific genetic markers (KRAS mutation and ST2 protein). The main goal is to find the safest dose and …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1 • Sponsor: Georgetown University • Aim: Disease control
Last updated Apr 03, 2026 21:26 UTC
-
New pill targets 'Undruggable' cancer mutations in major trial
Disease control Recruiting nowThis study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC